Actavis, which is being acquired by Watson Pharmaceuticals (WPI +0.2%), says that on June 29 it...
Actavis, which is being acquired by Watson Pharmaceuticals (WPI +0.2%), says that on June 29 it received tentative approval from the FDA for Guanfacine Extended-Release Tablets, a generic equivalent to Shire's (SHPGY -2.5%) Intuniv. Intuniv had US sales of approximately $342M for the 12 months ending March 31.
From other sites
Video at CNBC.com (Mon, 11:40AM)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 30, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs